University of Michigan Health System, Ann Arbor, MI, USA.
J Med Econ. 2013;16(6):801-8. doi: 10.3111/13696998.2013.787427. Epub 2013 Apr 4.
To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes.
This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 October 2006 and 30 September 2008 and with continuous enrollment in the health insurance plan at least 1 year before and 1 year after their index dornase alfa claim. Adherence was measured with the medication possession ratio (MPR). Multivariate models were used to estimate the relationship between adherence and exacerbations, utilization, and cost.
Nine hundred and seven patients met the inclusion criteria. The mean age was 19.5 years (SD = 11.5) and 49.1% were female. Overall MPR was 0.59 and by age was 0.66 for patients of 5-12 years, 0.57 for 13-20 years, 0.54 for 21-30 years, and 0.56 for patients ≥31 years. Adherence was better in fall and winter than in spring and summer. There was no statistically significant difference in the proportion of patients with inpatient respiratory exacerbations across groups with low (<0.5), moderate (0.5-0.79), and high (≥0.8) adherence (24.5%, 22.3%, and 19.1%, respectively, p = 0.250). There was a trend toward higher total charges in more-adherent patients (mean $58,612 in the least-adherent group and mean $69,427 in the most adherent group, p = 0.107). In multivariate models, MPR was not significantly associated with the risk of inpatient respiratory exacerbations (hazard ratio = 1.16 for MPR <0.5 vs ≥0.8; 95% CI = 0.83-1.61).
Study data were derived from insurance claims; adherence measures were based on prescription fills, not observed medication use.
Adherence to dornase alfa was generally low, but varied by age and season. Adherence was not found to be significantly associated with respiratory exacerbations or total charges, but was associated with shorter hospital length of stay.
调查商业保险覆盖的囊性纤维化(CF)患者对脱氧核糖核酸酶阿尔法治疗的依从性,并研究其对健康和经济结果的影响。
本回顾性队列分析纳入了 2006 年 10 月 1 日至 2008 年 9 月 30 日期间至少有一次脱氧核糖核酸酶阿尔法(Pulmozyme)药房报销记录,且在其脱氧核糖核酸酶阿尔法报销记录前至少 1 年和后 1 年持续参加健康保险计划的 CF 患者。采用药物持有率(MPR)来衡量依从性。采用多变量模型来估计依从性与恶化、利用和成本之间的关系。
907 名患者符合纳入标准。平均年龄为 19.5 岁(标准差=11.5),49.1%为女性。总体 MPR 为 0.59,5-12 岁患者为 0.66,13-20 岁患者为 0.57,21-30 岁患者为 0.54,≥31 岁患者为 0.56。依从性在秋季和冬季要好于春季和夏季。低(<0.5)、中(0.5-0.79)和高(≥0.8)依从性组的住院呼吸道恶化患者比例无统计学差异(分别为 24.5%、22.3%和 19.1%,p=0.250)。在更依从的患者中,总费用有升高趋势(依从性最低组的平均费用为 58612 美元,依从性最高组的平均费用为 69427 美元,p=0.107)。在多变量模型中,MPR 与住院呼吸道恶化风险无显著相关性(MPR<0.5 与≥0.8 相比的风险比为 1.16;95%置信区间=0.83-1.61)。
研究数据来自保险索赔;依从性测量基于处方数量,而非实际用药情况。
脱氧核糖核酸酶阿尔法的依从性总体较低,但因年龄和季节而异。依从性与呼吸道恶化或总费用无显著相关性,但与住院时间缩短有关。